[Skip to Content]
[Skip to Content Landing]
Views 1,972
Citations 0
Clinical Trials Update
April 24, 2018

Prazosin May Not Reduce Nightmares in Veterans With PTSD

JAMA. 2018;319(16):1649. doi:10.1001/jama.2018.4741

Prazosin, an α1-adrenoreceptor antagonist, did not reduce nightmare frequency or intensity or improve sleep in military veterans with posttraumatic stress disorder (PTSD), concluded a trial in the New England Journal of Medicine.

The 304 participants with PTSD were randomly assigned to receive placebo or prazosin for 26 weeks—at a dose higher than in most previous trials, the authors noted.